Literature DB >> 18255007

Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients.

Seema Basi1, Julia B Lewis.   

Abstract

Microalbuminuria has been shown to be a risk factor for adverse renal and cardiovascular outcomes in patients with diabetes mellitus. This risk appears to increase with higher levels of albuminuria. There is also evidence that reducing the level of albuminuria improves these outcomes. This review focuses on the most recent advances in this area and reviews literature over the past year on this topic.

Entities:  

Mesh：

Year:  2007        PMID： 18255007     DOI： 10.1007/s11892-007-0074-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  26 in total

1.  Standards of medical care in diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients.

Authors:  B Sulikowska; H Olejniczak; M Muszyńska; G Odrowaz-Sypniewska; A Gaddi; C Savini; A F G Cicero; L Laghi; J Manitius
Journal:  Am J Nephrol       Date:  2006-12-21       Impact factor: 3.754

3.  Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.

Authors:  Giovanni Gambaro; Ida Kinalska; Adrian Oksa; Peter Pont'uch; Miluse Hertlová; Jindrich Olsovsky; Jacek Manitius; Domenico Fedele; Stanislaw Czekalski; Jindriska Perusicová; Jan Skrha; Jan Taton; Wladyslaw Grzeszczak; Gaetano Crepaldi
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

4.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

5.  Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.

Authors:  George L Bakris; Luis M Ruilope; Stephen O McMorn; Wayde M Weston; Mark A Heise; Martin I Freed; Lisa E Porter
Journal:  J Hypertens       Date:  2006-10       Impact factor: 4.844

Review 6.  Albumin-like material in urine.

Authors:  Wayne D Comper; Tanya M Osicka
Journal:  Kidney Int Suppl       Date:  2004-11       Impact factor: 10.545

Review 7.  Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.

Authors:  Nagesh S Anavekar; Daniel J Gans; Tomas Berl; Richard D Rohde; William Cooper; Amitabha Bhaumik; Lawrence G Hunsicker; Jean-Lucien Rouleau; Julia B Lewis; Clive Rosendorff; Jerome G Porush; Paul L Drury; Enric Esmatjes; Itamar Raz; Phillippe Vanhille; Franceso Locatelli; Samuel Goldhaber; Edmund J Lewis; Marc A Pfeffer
Journal:  Kidney Int Suppl       Date:  2004-11       Impact factor: 10.545

8.  Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10).

Authors:  Hiroki Yokoyama; Koichi Kawai; Masashi Kobayashi
Journal:  Diabetes Care       Date:  2007-04       Impact factor: 19.112

9.  Effects of aerobic exercise on microalbuminuria and enzymuria in type 2 diabetic patients.

Authors:  Gordana Lazarevic; Slobodan Antic; Predrag Vlahovic; Vidosava Djordjevic; Lilika Zvezdanovic; Vladisav Stefanovic
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

10.  Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes.

Authors:  Shin-ichi Araki; Masakazu Haneda; Daisuke Koya; Hideki Hidaka; Toshiro Sugimoto; Motohide Isono; Keiji Isshiki; Masami Chin-Kanasaki; Takashi Uzu; Atsunori Kashiwagi
Journal:  Diabetes       Date:  2007-03-14       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.